Everything below concerns research chemical. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-10-13. Where a claim depends on a specific study, the study is described rather than over-claimed.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small-molecule ligand; not a hormone or peptide |
| Molecular formula | C20H24ClN3O4S | Reported for the free base |
| CAS Registry Number | 1379686-30-2 | Unique chemical identifier |
| Common synonyms | SR9009; stenabolic | Stenabolic is informal and not an official name |
| Reported targets | REV-ERBα and REV-ERBβ | Nuclear receptors linked to circadian and metabolic regulation |
Identity and purity testing for SR9009 commonly uses liquid chromatography coupled with tandem mass spectrometry. This method separates the compound from matrix components and detects it by mass-to-charge transitions, providing sensitive and specific confirmation. Nuclear magnetic resonance spectroscopy can support structural identification, while high-performance liquid chromatography with ultraviolet detection may estimate purity. Because online products labeled as SR9009 may contain other substances or no active compound at all, independent verification is important in research settings. Certificates of analysis are useful but not a substitute for in-house testing.
Laboratory samples of SR9009 are typically supplied as a white to off-white powder. The compound dissolves readily in organic solvents such as dimethyl sulfoxide and ethanol, while its solubility in water is low. Because of this solubility profile, researchers often prepare concentrated stock solutions in an organic solvent before diluting them into aqueous assay buffers. Light exposure, moisture, and repeated freeze-thaw cycles can degrade many small molecules, so handling procedures usually aim to minimize these factors. Purity is commonly checked before use.
Storage conditions for research-grade SR9009 generally involve a freezer at approximately minus twenty degrees Celsius, sometimes lower for long-term preservation. Containers should remain tightly closed and protected from light. Desiccants may be used to limit moisture uptake. Solutions are often stored in aliquots to avoid repeated warming and cooling. Stability data for the compound under various conditions are limited, so laboratories typically follow supplier recommendations and verify performance through periodic analytical checks rather than assuming indefinite stability.
Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.
Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.
The BioBricks assembly standard was described and introduced by Tom Knight in 2003 and it has been constantly updated since then. Currently, the most commonly used BioBricks standard is the assembly standard 10, or BBF RFC 10. BioBricks defines the prefix and suffix sequences required for a DNA part to be compatible with the BioBricks assembly method, allowing the joining of all DNA parts which are in the BioBricks format. The prefix contains the restriction sites for EcoRI, NotI and XBaI, while the suffix contains the SpeI, NotI and PstI restriction sites. Outside of the prefix and suffix regions, the DNA part must not contain these restriction sites. To join two BioBrick parts together, one of the plasmids is digested with EcoRI and SpeI while the second plasmid is digested with EcoRI and XbaI. The two EcoRI overhangs are complementary and will thus anneal together, while SpeI and XbaI also produce complementary overhangs which can also be ligated together. As the resulting plasmid contains the original prefix and suffix sequences, it can be used to join with more BioBricks parts. Because of this property, the BioBricks assembly standard is said to be idempotent in nature. However, there will also be a "scar" sequence (either TACTAG or TACTAGAG) formed between the two fused BioBricks.
=== Pregnancy === Oxazepam, when taken during the third trimester, causes a definite risk to the neonate, including a severe benzodiazepine withdrawal syndrome including hypotonia, reluctance to suck, apnoeic spells, cyanosis, and impaired metabolic responses to cold stress. Floppy infant syndrome and sedation in the newborn may also occur. Symptoms of floppy infant syndrome and the neonatal benzodiazepine withdrawal syndrome have been reported to persist from hours to months after birth.
== Organization == IMA Life is one of the four main divisions of the IMA group. IMA has 4 divisions dedicated to business areas in the main packaging and processing sectors: IMA Flavour (Tea & Coffee Packaging Solutions), IMA Active Division (Solid Dose Solutions), IMA Life (Aseptic Processing & Freeze Drying Solutions) and IMA Safe (Packaging Solutions). The last three business areas also manage companies operating in their respective sectors. The parent company, IMA is a multinational Italian company based in Bologna, Italy with a consolidated turnover of 505.8 million Euros.
=== Wild birds === Wildlife, including wild and migratory birds, serve as indicators of ecosystem health. They act as a reservoir for zoonotic diseases and antimicrobial-resistant organisms. Birds are a key link between the transmission of zoonotic diseases to human populations. By the same token, increased contact between wild birds and human populations (including domesticated animals), has increased the amount of anti-microbial resistance (AMR) to the bird population. The introduction of AMR to wild birds positively correlates with human pollution and increased human contact. Additionally, wild birds can participate in horizontal gene transfer with bacteria, leading to the transmission of antibiotic-resistant genes (ARG). For simplicity, wild bird populations can be divided into two major categories, wild sedentary birds and wild migrating birds. Wild sedentary bird exposure to AMR is through increased contact with densely populated areas, human waste, domestic animals, and domestic animal/livestock waste. Especially if they are predators, wild, sedentary birds can come into contact with prey that interact more closely with humans. Wild migrating birds interact with sedentary birds in different environments along their migration route. This increases the rate and diversity of AMR across varying ecosystems. Neglect of wildlife in the global discussions surrounding health security and AMR, creates large barriers to true AMR surveillance.
Sources: en.wikipedia.org
Other forms are due to different diseases causing overabundant or abnormal protein production – such as with overproduction of immunoglobulin light chains (termed AL amyloidosis), or with continuous overproduction of acute phase proteins in chronic inflammation (which can lead to AA amyloidosis). About 60 amyloid proteins have been identified so far. Of those, at least 36 have been associated with a human disease. All amyloid fibril proteins start with the letter "A" followed by the protein suffix (and any applicable specification). See below for a list of amyloid fibril proteins which have been found in humans:
== Chemistry == Methyl blue ([[4-[Bis[4-[(sulfophenyl)amino]phenyl]methylene]-2,5-cyclohexadien-1-ylidene]amino]-benzenesulfonic acid disodium salt) is distinctly different from methylene blue ([7-(dimethylamino)phenothiazin-3-ylidene]-dimethylazanium;chloride) in structure, function and uses, and must not be confused. Its uses include staining histology samples for collagen, and for fungal structures.
== Failsafes and avoiding false-positives == A pseudothrombocytopenia false-positive result may occur when automated platelet counting devices are used. As a means of double checking the results, the patient's blood sample is often examined under a microscope. If the clumping is visible and the number of platelets appears normal, pseudothrombocytopenia may be concluded. A second sample run with a different anticoagulant such as sodium citrate (blue top tube) to confirm the finding of pseudothrombocytopenia may be requested if there are doubts or concerns. Other alternative anticoagulants are sodium fluoride, CPT (trisodium citrate, pyridoxal 5′-phosphate and tris), CTAD (citrate, theophylline, adenosine, and dipyridamole), magnesium sulfate and acid-citrate-dextrose.
While transformed, he wields the D-Sword Vega (ディーソード・ベガ, Dī Sōdo Bega), which possesses a gun function and allows him to perform the Vega Tornado Slash (ベガトルネードスラッシュ, Bega Torunēdo Surasshu) attack and the Vega Slash (ベガスラッシュ, Bega Surasshu) finisher. He also rides the S.P.D. Helicopter (S.P.D.ヘリコプター, Esu Pī Dī Herikoputā). Doggie Kruger is voiced by Tetsu Inada (稲田 徹, Inada Tetsu).
=== US bases === In legal analysis of the crisis, some commentators suggested sovereign bases as a solution, similar to the United Kingdom's retention of sovereign base areas in Cyprus, under which limited territory is held under foreign sovereignty primarily for military purposes. Commentators suggested that such a model could allow a foreign power to exercise sovereign control over specific installations in Greenland without a broader transfer of territory, though the proposal was described as legally complex and politically contentious. Danish MP Sascha Faxe said giving up any sovereignty is completely out of the question, specifically stating that the Cyprus situation is not an option, whilst emphasising that military bases already have a significant degree of operational autonomy and jurisdiction under existing agreements, in line with what is normal for US bases abroad. Both Danish and Greenland officials said sovereignty is not negotiable. On 26 January, Greenland's government said the idea of transferring "sovereignty" of any Greenlandic land, including bases, is not possible and described it as a "red line."
Sources: en.wikipedia.org
=== Nerve-associated macrophages === Nerve-associated macrophages or NAMs are those tissue-resident macrophages that are associated with nerves. Some of them are known to have an elongated morphology of up to 200μm
== Physical and chemical properties == Lipoic acid contains two sulfur atoms connected by a disulfide bond in the 1,2-dithiolane ring. It also carries a carboxylic acid group. It is considered to be oxidized relative to its acyclic relative dihydrolipoic acid, in which each sulfur exists as a thiol. It is a yellow solid. (R)-(+)-lipoic acid (RLA) occurs naturally, but (S)-(-)-lipoic acid (SLA) has been synthesized. For use in dietary supplement materials and compounding pharmacies, the USP established an official monograph for R/S-LA.
== Example values == A PDCAAS value of 1 is the highest, and 0 the lowest. The table shows the ratings of selected foods. Parenthesized values reflect the value without truncation. A few more values can be found in Boye et al. 2012. Note the use of several different scoring profiles in this work: "updated" versions of PDCAAS may use profiles different from the 1993 original.
The effects on the federal budget of the aging population and rapidly growing health care costs are already apparent over the 10-year horizon—especially for Social Security and Medicare—and will grow in size beyond the baseline period. Unless laws governing fiscal policy were changed—that is, spending for large benefit programs was reduced, increases in revenues were implemented, or some combination of those approaches was adopted—debt would rise sharply relative to GDP after 2027. During June 2012, Federal Reserve Chair Ben Bernanke recommended three objectives for fiscal policy: 1) Take steps to put the federal budget on a sustainable fiscal path; 2) Avoid unnecessarily impeding the ongoing economic recovery; and 3) Design tax policies and spending programs to promote a stronger economy. President Barack Obama in June 2012 stated:
== The company == GenSpera president and CEO Craig Dionne, PhD, co-founded GenSpera in 2003. He was previously vice president of biological research at Cephalon Inc., where he was responsible for neurobiology and oncology drug discovery. GenSpera was financed by a series of private placements beginning in 2007 and became publicly traded in late 2009.
Sources: en.wikipedia.org
SR9009 is a synthetic compound investigated as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is used in preclinical research on circadian rhythm and metabolism. It is not an approved drug.
No. It has no approved medical indication, and human safety and efficacy data are limited. It appears in research chemical markets and is banned by some sports authorities.
Natural ligands include heme and certain metabolites; SR9009 is a synthetic small molecule with higher potency and selectivity in some assays. Its effects depend on cell type and timing. It is not a naturally occurring compound.
SR9009 is a synthetic REV-ERB agonist used in laboratory research. It is not an approved drug, and its effects in humans are not well characterized. It is often sold as a research chemical under the name Stenabolic.